Can tobramycin inhalation be improved with a jet nebulizer?

Therapeutic Drug Monitoring

Volumn 21, Issue 6, 1999, Pages 618-624

  Le Brun, Paul P H ^a   Vinks, Alexander A T M M ^a   Touw, Daan J ^b   Hekelaar, Nicole ^c   Mannes, Gregor P M ^c   Brimicombe, Roland W ^c   Frijlink, Erik H W ^d   Heijerman, Harry G M ^c  

^a Central Hospital Pharmacy   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEYENBURG HOSPITAL   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Inhalation; Jet nebulizer; Pharmacokinetics; Tobramycin

Indexed keywords

TOBRAMYCIN;

ADULT; AEROSOL; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; CYSTIC FIBROSIS; DEVICE; DRUG EFFECT; DRUG HALF LIFE; EPITHELIUM CELL; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MALE; NEBULIZATION; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; ADULT; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS; PILOT PROJECTS; TIME FACTORS; TOBRAMYCIN;

EID: 0032698373     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199912000-00007     Document Type: Article

References (28)

1. White R, Woodward S, Leppert M, et al. A closely linked genetic marker for cystic fibrosis. Nature 1985;318:382-4.
2. Koch C, Høiby N. Pathogenesis of cystic fibrosis. Lancer 1993; 341:1065-8.
3. Marks MI. The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. J Pediatr 1981;98:173-9.
4. British Thoracic Society Nebuliser Project Group. Guidelines. Thorax 1997;52(Suppl 2):S3.
5. Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-88.
6. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, double blind randomized study of aerosolized tobramycin for early treatment of pseudomonas aeruginosa colonization in cystic fibrosis. Ped Pulmonol 1998;25:88-92.
7. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
8. Touw DJ, Jacobs FAH, Brimicombe RW, Heijerman HGM, Bakker W, Breimer DD. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother 1997;41:184-7.
9. Smith AL, Ramsey BW. Aerosol administration of antibiotics. Pediatr Pulmonol 1995;11:68-9.
10. Toso C, Williams DM, Noone PG. Inhaled antibiotics in cystic fibrosis: A review. Ann Pharmacother 1996;30:840-50.
11. Davis PB, Drumm M, Konstan MW. Cystic Fibrosis. Am J Respir Crit Care Med 1996;154:1229-56.
12. Mukhopadhyay S, Singh M, Cater JI, Ogston S, Franklin M, Olver RE. Nebulized antipseudomonal antibiotic therapy in cystic fibrosis: a meta-analysis of benefits and risks. Thorax 1996;51:364-8.
13. Touw DJ, Brimicombe RW, Hodson ME, Heijerman HGM, Bakker W. Inhalation of antibiotics in cystic fibrosis. Eur Respir J 1995;8:1594-1604.
14. Webb AK, Dodd ME. Nebulized antibiotics for adults with cystic fibrosis. Thorax 1997;52(suppl 2):S69-S71.
15. Smaldone GC. Factors determining aerosol deposition. Ped Pulm 1998(suppl 17);21:176-7.
16. Le Brun PPH, deBoer AH, Gjaltema D, Hagedoorn P, Heijerman HGM, Frijlink HW. Inhalation of tobramycin in Cystic Fibrosis. Part 1: The choice of a nebulizer. Int J Pharm (accepted for publication).
17. Touw DJ, Graaf AI de, Goede P de. Evaluation of a fluorescence polarographic immunoassay with increased sensitivity for measurements of low concentrations of tobramycin in serum. Ther Drug Monit 1996;18:189-93.
18. Jelliffe RW, Schumitzky A, van Guilder M, et al. Individualizing drug dosage regimens: roles of population pharmacokinetics and dynamic models, Bayesian fitting, and adaptive control. Ther Drug Mon 1993;15:380-93.
19. Jelliffe RW. Creatinine clearance: a bedside estimate. Ann Intern Med 1973;79:604-5.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
21. Touw DJ, Vinks AATMM, Jacobs F, et al. Creatinine clearance as predictor of tobramycin elimination in adult patients with cystic fibrosis. Ther Drugs Mon 1996;18:562-569.
22. Proost JH, Meijer DKF. MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput Biol Med 1992;22:155-63.
23. Gabrielsson J, Weiner D, eds. Pharmacokinetic/Pharmacodynamic Data Analysis: Concepts and Applications. 2nd edition. Stockholm: Swedish Pharmaceutical Press; 1997:309.
24. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker;1982.
25. Touw DJ, Vinks AATMM, Neef C. Pharmacokinetic modelling of intravenous tobramycin in adolescent and adult patients with cystic fibrosis using the nonparametric expectation maximization (NPEM) algorithm. Pharm World Sci 1997;19:142-51.
26. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamycin in cystic fibrosis. Am Rev Respir Dis 1987;1445-9.
27. Mukhopadhyay S, Staddon GE, Eastman C, et al. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis. Resp Med 1994;88:203-11.
28. Mouton JW, Kerrebijn KF. Antibacterial therapy in cystic fibrosis. Med Clin North Am 1990;74:837-859.